Our patient sample had similar features to other ALK+ NSCLC populations included in several real-world studies [27–32]: half the patients were female, with a mean age below 60 years, most were non-smokers, and they presented stage IV disease and adenocarcinoma histology. This evidence concerns the gene ALK and adenocarcinoma.